- Home
- AXIL vs LSTA Comparison
AXIL vs LSTA Comparison
Compare AXIL & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- LSTA
- Stock Information
- Founded
- AXIL 2015
- LSTA 1980
- Country
- AXIL United States
- LSTA United States
- Employees
- AXIL N/A
- LSTA N/A
- Industry
- AXIL Package Goods/Cosmetics
- LSTA Misc Health and Biotechnology Services
- Sector
- AXIL Consumer Discretionary
- LSTA Health Care
- Exchange
- AXIL Nasdaq
- LSTA Nasdaq
- Market Cap
- AXIL 25.6M
- LSTA 24.2M
- IPO Year
- AXIL N/A
- LSTA N/A
- Fundamental
- Price
- AXIL $4.18
- LSTA $2.77
- Analyst Decision
- AXIL
- LSTA Strong Buy
- Analyst Count
- AXIL 0
- LSTA 1
- Target Price
- AXIL N/A
- LSTA $15.00
- AVG Volume (30 Days)
- AXIL 6.3K
- LSTA 14.6K
- Earning Date
- AXIL 10-10-2024
- LSTA 11-12-2024
- Dividend Yield
- AXIL N/A
- LSTA N/A
- EPS Growth
- AXIL 144.51
- LSTA N/A
- EPS
- AXIL 0.24
- LSTA N/A
- Revenue
- AXIL $27,243,542.00
- LSTA N/A
- Revenue This Year
- AXIL N/A
- LSTA N/A
- Revenue Next Year
- AXIL N/A
- LSTA N/A
- P/E Ratio
- AXIL $16.92
- LSTA N/A
- Revenue Growth
- AXIL 7.30
- LSTA N/A
- 52 Week Low
- AXIL $3.78
- LSTA $2.05
- 52 Week High
- AXIL $14.00
- LSTA $3.83
- Technical
- Relative Strength Index (RSI)
- AXIL 46.57
- LSTA 39.99
- Support Level
- AXIL $4.00
- LSTA $2.75
- Resistance Level
- AXIL $4.58
- LSTA $2.94
- Average True Range (ATR)
- AXIL 0.22
- LSTA 0.21
- MACD
- AXIL -0.00
- LSTA -0.01
- Stochastic Oscillator
- AXIL 15.19
- LSTA 7.81
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.